This is a Phase 3 clinical study for people 12 years and older with moderate to severe atopic dermatitis (eczema) that hasn’t responded well to prescription creams or when those treatments aren’t suitable. The study will test a new injectable medication called amlitelimab to see how safe and effective it is compared to a placebo.
What to Expect
Participants will be randomly assigned to one of three groups. Two groups will receive the amlitelimab treatment, and one group will receive a placebo (a treatment without active medication). Neither participants nor the researchers will know who is in which group during the study.
Treatment Period
- Up to 44 weeks
- Potential to join a follow-up study called the EFC17600 (ESTUARY) extension study.
The treatment will last for up to 24 weeks.
Trial Requirements
- Age 13+
Urgently Recruiting
Trial Details
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2)
